72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers. (25th November 2018) - Quintela-Fandino, M; Manso Sànchez, L M; Holgado Martín, E; Moreno, M C; Morales Murillo, S; Bermejo De Las Heras, B; Malon Gimenez, D; Colomer Bosch, R; Gonzalez Cortijo, L; Hornedo, J; Mouron, S; Muñoz, M; et al.